VincentChungMD

Clinical Trials

• Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2003 Dec 22

  Completed

  Phase 2

• Dasatinib in Treating Patients With Stage IV Pancreatic Cancer Start of enrollment: 2007 Sep 01

  Terminated

  Phase 2

• Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Start of enrollment: 2011 Oct 01

  Completed

  Phase 1

• Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Start of enrollment: 2012 Feb 01

  Completed

  Phase 1, Phase 2

• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20

  Active, not recruiting

  Phase 1

• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12

  Active, not recruiting

  Phase 1

• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Start of enrollment: 2012 Aug 01

  Completed

  Phase 2

• Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01

  Terminated

  Phase 3

• Phase I Study of LB-100 With Docetaxel in Solid Tumors Start of enrollment: 2013 Feb 01

  Completed

  Phase 1

• Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23

  Terminated

  Phase 1

• 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer Start of enrollment: 2014 Nov 19

  Active, not recruiting

  Not Applicable

• Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction Start of enrollment: 2013 Dec 01
• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10

  Active, not recruiting

  Phase 1

• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations Start of enrollment: 2021 Feb 22

  Recruiting

  Phase 2

• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer Start of enrollment: 2021 Jul 21

  Recruiting

  Phase 2

• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Start of enrollment: 2021 Oct 04

  Active, not recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• AOH1996 for the Treatment of Refractory Solid Tumors Start of enrollment: 2022 Aug 12

  Active, not recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer Start of enrollment: 2022 Jan 25

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Start of enrollment: 2023 Apr 14

  Recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer Start of enrollment: 2024 May 13

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Join now to see all